Literature DB >> 12401661

New drugs for treatment of gastric cancer.

P Schöffski1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12401661     DOI: 10.1093/annonc/mdf633

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  5 in total

1.  A phase II study of weekly docetaxel and cisplatin plus oral tegafur/uracil and leucovorin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer.

Authors:  C-P Li; J-S Chen; L-T Chen; C-J Yen; K-D Lee; W-P Su; P-C Lin; C-H Lu; H-J Tsai; Y Chao
Journal:  Br J Cancer       Date:  2010-10-05       Impact factor: 7.640

2.  Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma.

Authors:  S Falk; A Anthoney; M Eatock; E Van Cutsem; J Chick; H Glen; J W Valle; D W Drolet; D Albert; D Ferry; J Ajani
Journal:  Br J Cancer       Date:  2006-08-01       Impact factor: 7.640

3.  Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer.

Authors:  M Moehler; A Eimermacher; J Siebler; T Höhler; A Wein; M Menges; D Flieger; T Junginger; T Geer; E Gracien; P R Galle; M Heike
Journal:  Br J Cancer       Date:  2005-06-20       Impact factor: 7.640

4.  An open, multi-centre, phase II clinical trial to evaluate the efficacy and safety of paclitaxel, UFT, and leucovorin in patients with advanced gastric cancer.

Authors:  Y Chao; C P Li; T Y Chao; W C Su; R K Hsieh; M F Wu; K H Yeh; W Y Kao; L T Chen; A L Cheng
Journal:  Br J Cancer       Date:  2006-06-27       Impact factor: 7.640

5.  Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?

Authors:  V Catalano; F Graziano; D Santini; S D'Emidio; A M Baldelli; D Rossi; B Vincenzi; P Giordani; P Alessandroni; E Testa; G Tonini; G Catalano
Journal:  Br J Cancer       Date:  2008-11-04       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.